Terms: = Breast cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Clinical Outcome
180 results:
1. Caveolin-1 gene expression provides additional prognostic information combined with PAM50 risk of recurrence (ROR) score in breast cancer.
Godina C; Belting M; Vallon-Christersson J; Isaksson K; Bosch A; Jernström H
Sci Rep; 2024 Mar; 14(1):6675. PubMed ID: 38509243
[TBL] [Abstract] [Full Text] [Related]
2. Conditional generative adversarial network driven radiomic prediction of mutation status based on magnetic resonance imaging of breast cancer.
Huang ZH; Chen L; Sun Y; Liu Q; Hu P
J Transl Med; 2024 Mar; 22(1):226. PubMed ID: 38429796
[TBL] [Abstract] [Full Text] [Related]
3. Genetic Ancestry-specific Molecular and Survival Differences in Admixed Patients With breast cancer.
Telonis AG; Rodriguez DA; Spanheimer PM; Figueroa ME; Goel N
Ann Surg; 2024 May; 279(5):866-873. PubMed ID: 38073557
[TBL] [Abstract] [Full Text] [Related]
4. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
5. High Level of GMFG Correlated to Poor clinical outcome and Promoted Cell Migration and Invasion through EMT Pathway in Triple-Negative breast cancer.
Zhao Y; Wei X; Li J; Diao Y; Shan C; Li W; Zhang S; Wu F
Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372337
[TBL] [Abstract] [Full Text] [Related]
6. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
Gravis G; Marino P; Olive D; Penault-LLorca F; Delord JP; Simon C; Lamrani-Ghaouti A; Sabatier R; Ciccolini J; Boher JM
BMC Cancer; 2023 May; 23(1):393. PubMed ID: 37131154
[TBL] [Abstract] [Full Text] [Related]
7. MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients.
Wang G; Miao C; Mo L; Kahlert UD; Wu J; Ou M; Huang R; Feng R; Pang W; Shi W
Front Immunol; 2022; 13():1048503. PubMed ID: 36582246
[TBL] [Abstract] [Full Text] [Related]
8. The Pan-cancer Multi-Omics Landscape of FOXO Family Relevant to clinical outcome and Drug Resistance.
Xie J; Zhang J; Tian W; Zou Y; Tang Y; Zheng S; Wong CW; Deng X; Wu S; Chen J; Mo Y; Xie X
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555288
[TBL] [Abstract] [Full Text] [Related]
9. Glucose metabolism and lncRNAs in breast cancer: Sworn friend.
Xu JL; Xu Q; Wang YL; Xu D; Xu WX; Zhang HD; Wang DD; Tang JH
Cancer Med; 2023 Feb; 12(4):5137-5149. PubMed ID: 36426411
[TBL] [Abstract] [Full Text] [Related]
10. Dummy run quality assurance study in the Korean Radiation Oncology Group 19 - 09 multi-institutional prospective cohort study of breast cancer.
Kim M; Park B; Kim H; Kim YJ; Choi DJ; Chung W; Kim YJ; Shin HS; Im JH; Suh CO; Kim JH; Ha B; Kim MY; Park J; Lee J; Ahn SJ; Lee SY; Kusumawidjaja G; Lim F; Cho WK; Kim H; Choi DH; Park W
Radiat Oncol; 2022 Nov; 17(1):186. PubMed ID: 36384804
[TBL] [Abstract] [Full Text] [Related]
11. Characterization of the CpG island methylator phenotype subclass in papillary thyroid carcinoma.
Gu P; Zeng Y; Ma W; Zhang W; Liu Y; Guo F; Ruan X; Chi J; Zheng X; Gao M
Front Endocrinol (Lausanne); 2022; 13():1008301. PubMed ID: 36353231
[TBL] [Abstract] [Full Text] [Related]
12. Artificial Intelligence in breast cancer Screening: Evaluation of FDA Device Regulation and Future Recommendations.
Potnis KC; Ross JS; Aneja S; Gross CP; Richman IB
JAMA Intern Med; 2022 Dec; 182(12):1306-1312. PubMed ID: 36342705
[TBL] [Abstract] [Full Text] [Related]
13. An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer.
Li XF; Fu WF; Zhang J; Song CG
BMC Cancer; 2022 Jun; 22(1):619. PubMed ID: 35668369
[TBL] [Abstract] [Full Text] [Related]
14. Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in breast cancer.
Xu Q; Chen S; Hu Y; Huang W
Front Immunol; 2021; 12():711433. PubMed ID: 34512634
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive analysis of BTN3A1 in cancers: mining of omics data and validation in patient samples and cellular models.
Liang F; Zhang C; Guo H; Gao SH; Yang FY; Zhou GB; Wang GZ
FEBS Open Bio; 2021 Sep; 11(9):2586-2599. PubMed ID: 34293829
[TBL] [Abstract] [Full Text] [Related]
16. PP1, PKA and DARPP-32 in breast cancer: A retrospective assessment of protein and mRNA expression.
Saidy B; Kotecha S; Butler A; Rakha EA; Ellis IO; Green AR; Martin SG; Storr SJ
J Cell Mol Med; 2021 Jun; 25(11):5015-5024. PubMed ID: 33991172
[TBL] [Abstract] [Full Text] [Related]
17. Predicting the clinical outcome of oral potentially malignant disorders using transcriptomic-based molecular pathology.
Sathasivam HP; Kist R; Sloan P; Thomson P; Nugent M; Alexander J; Haider S; Robinson M
Br J Cancer; 2021 Aug; 125(3):413-421. PubMed ID: 33972745
[TBL] [Abstract] [Full Text] [Related]
18. CD2 Is a Novel Immune-Related Prognostic Biomarker of Invasive breast Carcinoma That Modulates the Tumor Microenvironment.
Chen Y; Meng Z; Zhang L; Liu F
Front Immunol; 2021; 12():664845. PubMed ID: 33968066
[TBL] [Abstract] [Full Text] [Related]
19. Identification and development of an independent immune-related genes prognostic model for breast cancer.
Chen L; Dong Y; Pan Y; Zhang Y; Liu P; Wang J; Chen C; Lu J; Yu Y; Deng R
BMC Cancer; 2021 Mar; 21(1):329. PubMed ID: 33785008
[TBL] [Abstract] [Full Text] [Related]
20. NR3C2-Related Transcriptome Profile and clinical outcome in Invasive breast Carcinoma.
Lu J; Hu F; Zhou Y
Biomed Res Int; 2021; 2021():9025481. PubMed ID: 33564687
[TBL] [Abstract] [Full Text] [Related]
[Next]
